Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) is a progressive neurological disease with an average age of onset at 43 years and an average life expectancy of only three to five years after symptoms begin. ALSP is caus…
Infections in the brain can have serious consequences and are often fatal. The immune defense system works differently here than in the rest of the body. A team of researchers at TWINCORE—Center for Experimental and Clinical Infection Research in Hanov…
When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered patients immense hope. The long-awaited drug is a monoclonal antibody that depletes B cells—the immune cells that drive MS progressi…
Instead of using a patient’s own bone or titanium to repair skull fractures, researchers are working on using artificial materials. New research—surprisingly—shows that the body’s immune system helps strengthen artificial materials.
A team of physicians from Bochum are the first to successfully use CAR T-cell therapy to treat two patients with a rare autoimmune disease of the peripheral nervous system. This treatment modifies endogenous immune cells such that they can specifically…
Stroke remains one of the leading causes of death, disability, increased economic burden and decreased quality of life around the world. Current stroke therapies are time-limited and largely focused on restoring blood flow, and there are few which add…
Microglia are a specialized type of immune cell that accounts for about 10% of all cells within the brain and spinal cord. They function by eliminating infectious microbes, dead cells, and aggregated proteins, as well as soluble antigens that may endan…
The brain is a unique place. It is shielded from much of the body by the blood-brain barrier, meaning it’s protected from pathogens and potentially dangerous substances that might be in our blood. And historically, many scientists believed that separat…
Monash University scientists have identified a potential new drug target to alleviate neuroinflammation, which is reported in many neurodegenerative diseases, such as Alzheimer’s, Parkinson’s and motor neuron disease.
An international research team led by Professor Kiavash Movahedi from the Brussels Center for Immunology at the Vrije Universiteit Brussel has published unexpected results in the journal Immunity. Their study sheds new light on the possibility of effec…
